Literature DB >> 9740161

Catabolism in critical illness: estimation from urea nitrogen appearance and creatinine production during continuous renal replacement therapy.

M Leblanc1, L J Garred, J Cardinal, V Pichette, L Nolin, D Ouimet, D Geadah.   

Abstract

Thirty-eight intensive care unit (ICU) patients (26 men and 12 women with a mean age of 57.0 +/- 16.6 years) with acute renal failure (ARF) treated by venovenous continuous renal replacement therapy (CRRT) were evaluated while in relatively steady metabolic control. Twenty-seven were undergoing continuous venovenous hemodialysis, nine were undergoing continuous venovenous hemodiafiltration, and two were undergoing continuous venovenous hemofiltration. Periods of analysis varied between 24 and 408 hours (mean duration, 82.7 +/- 70.6 hours; median, 72 hours). Their mean Acute Physiology and Chronic Health Evaluation II (APACHE II) score within 24 hours of admission to the ICU was 21.3 +/- 6.3 and survival rate was 31.6%. Urea nitrogen and creatinine concentrations were determined every 6 to 12 hours in both serum (Cun and Cc, respectively) and effluent (spent dialysate and/or ultrafiltrate). The mean effluent rate was 1,472 +/- 580 mL/h and blood flow rate, 166 +/- 32 mL/min. Urine was collected daily for urea nitrogen and creatinine measurement. Urea nitrogen appearance rate (UnA) and creatinine production rate (Pc), calculated from urea nitrogen (UnMR) and creatinine mass removal (CMR) from both the effluent and the urine, using Garred mass balance equations and the Forbes-Bruining formula, allowed normalized protein catabolic rate (nPCR) and estimates of lean body mass (LBM) to be derived. Creatinine metabolic degradation rate (Dc), estimated by the Mitch formula, was included in the calculation. The lowest body weight recorded during the study period was considered as dry weight (BW). The creatinine index (CI) was also obtained. For each parameter, the results are presented as mean, median, and range values: UnMRe (from effluent), 13.6 +/- 7.2, 12.5, 1.6 to 32.6 mg/min; UnMRu (from urine), 0.13 +/- 0.40, 0, 0 to 2.30 mg/min; UnA, 13.6 +/- 7.0, 12.5, 3.8 to 32.1 mg/min; nPCR, 1.75 +/- 0.82, 1.60, 0.61 to 4.23 g/kg/d; CMRe (from effluent), 942.0 +/- 362.3, 918.0, 211.2 to 1,641.6 mg/d; CMRu (from urine), 44.4 +/- 138.8, 0, 0 to 698.5 mg/d; Dc, 94.6 +/- 49.9, 81.9, 31.0 to 294.1 mg/d; Pc total, 1,067.1 +/- 409.7, 1,053.7, 261.5 to 1,988.2 mg/d; LBM, 38.3 +/- 11.9, 37.9, 15.0 to 65.0 kg; LBM/BW ratio, 49.5% +/- 14.0%, 50.3%, 22.5% to 86.0%; and CI, 13.7 +/- 4.7, 14.2, 4.1 to 25.8 mg/kg/d. When Pc was estimated from the Cockcroft-Gault equations (as Pc'), the mean value for Pc and Pc' was similar (1,067.1 +/- 409.7 v 1,284.9 +/- 484.1 mg/d), but there were relatively large differences for the majority of cases. A positive correlation was observed between UnA and Pc (R = 0.42). Serum albumin and LBM/BW correlated poorly (R = 0.20). Outcome was weakly related to UnA and to nPCR (R = 0.29 and R = 0.31, respectively). Urea nitrogen appearance appears widely variable in critically ill ARF patients. This simple approach can provide useful information for an easy estimate of net protein catabolism in critically ill patients with ARF undergoing CRRT.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9740161     DOI: 10.1053/ajkd.1998.v32.pm9740161

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  12 in total

1.  Section 3: Prevention and Treatment of AKI.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-03

Review 2.  [Nutrition and renal insufficiency].

Authors:  W Druml
Journal:  Med Klin Intensivmed Notfmed       Date:  2013-06-08       Impact factor: 0.840

3.  Toward the optimal dose metric in continuous renal replacement therapy.

Authors:  Rolando Claure-Del Granado; Etienne Macedo; Glenn M Chertow; Sharon Soroko; Jonathan Himmelfarb; T Alp Ikizler; Emil P Paganini; Ravindra L Mehta
Journal:  Int J Artif Organs       Date:  2012-06       Impact factor: 1.595

4.  [Metabolic management and nutrition in critically ill patients with renal dysfunction : Recommendations from the renal section of the DGIIN, ÖGIAIN, and DIVI].

Authors:  W Druml; M Joannidis; S John; A Jörres; M Schmitz; J Kielstein; D Kindgen-Milles; M Oppert; V Schwenger; C Willam; A Zarbock
Journal:  Med Klin Intensivmed Notfmed       Date:  2018-05-03       Impact factor: 0.840

5.  Risk of contrast induced nephropathy in the critically ill: a prospective, case matched study.

Authors:  Cynthia M Cely; Roland M H Schein; Andrew A Quartin
Journal:  Crit Care       Date:  2012-12-12       Impact factor: 9.097

6.  Effects of continuous renal replacement therapy on renal inflammatory cytokines during extracorporeal membrane oxygenation in a porcine model.

Authors:  Hu Yimin; Yu Wenkui; Shi Jialiang; Chen Qiyi; Shen Juanhong; Lin Zhiliang; He Changsheng; Li Ning; Li Jieshou
Journal:  J Cardiothorac Surg       Date:  2013-04-29       Impact factor: 1.637

Review 7.  Parenteral nutrition in patients with renal failure - Guidelines on Parenteral Nutrition, Chapter 17.

Authors:  W Druml; H P Kierdorf
Journal:  Ger Med Sci       Date:  2009-11-18

Review 8.  Bench-to-bedside review: metabolism and nutrition.

Authors:  Michaël P Casaer; Dieter Mesotten; Miet R C Schetz
Journal:  Crit Care       Date:  2008-08-19       Impact factor: 9.097

Review 9.  Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1).

Authors:  John A Kellum; Norbert Lameire
Journal:  Crit Care       Date:  2013-02-04       Impact factor: 9.097

10.  A new high protein-to-energy enteral formula with a whey protein hydrolysate to achieve protein targets in critically ill patients: a prospective observational tolerability study.

Authors:  Franziska Tedeschi-Jockers; Simona Reinhold; Alexa Hollinger; Daniel Tuchscherer; Caroline Kiss; Lukas Gantner; Katrin Ledergerber; Sibylle Zimmermann; Jonas Scheuzger; Jan Huber; Martin Siegemund
Journal:  Eur J Clin Nutr       Date:  2021-06-24       Impact factor: 4.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.